Published in Clinical Oncology Week, December 8th, 2003
"Imatinib mesylate (IM, STI 571, Glivec(R)) can induce a high rate of complete cytogenetic response (CCR) in chronic myeloid leukemia (CML) patients, although to date the majority of patients continue to have detectable disease by sensitive reverse transcription polymerase chain reaction (RT-PCR)," oncologists in Scotland explained. "It is therefore possible that these patients may ultimately relapse and require treatment such as autologous peripheral blood stem cell transplant (APBSCT)."
In a recent study, M.W. Drummond and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.